Beijing Strong Biotechnologies expands product portfolio with new device registrations

Beijing Strong Biotechnologies Co., Ltd. recently announced the acquisition of two new medical device registration certificates issued by the Beijing Municipal Medical Products Administration. The newly registered devices are the "Fully Automatic Coagulation Analyzer (Model MDC7600)" and the "Fully Automatic Chemiluminescence Immunoassay Analyzer (Model Gi 6000)." Both certificates are valid from their approval date until September 4, 2030.

The Fully Automatic Coagulation Analyzer (Model MDC7600) is intended for quantitative analysis of analytes in human samples when used with compatible reagents. The Fully Automatic Chemiluminescence Immunoassay Analyzer (Model Gi 6000) is designed for qualitative or quantitative detection of analytes in human serum, plasma, whole blood, urine, and cerebrospinal fluid samples. Its applications include measuring vitamins, amino acids and blood drug concentrations, hormones, markers for myocardial diseases, infectious diseases, autoantibodies, tumor-related antigens, proteins and polypeptides, kidney and liver disease markers, immune function assessments, allergen-related items, coagulation tests, and other enzyme assays.

The company stated that obtaining these registration certificates enriches its product categories and positively impacts its core competitiveness and future development. However, it clarified that these acquisitions are not expected to have a significant impact on the company's recent production, operations, or performance. Investors are advised to be aware of potential risks.